Ibogaine for Opioid Addiction — Research & Evidence

Interrupts Withdrawal in Hours

Multiple clinical studies show ibogaine dramatically reduces or eliminates opioid withdrawal symptoms within 1–4 hours of administration — a result no other treatment can achieve.

Resets Opioid Receptor Sensitivity

Ibogaine's NMDA antagonism reverses the neuroadaptations underlying opioid dependence, restoring receptor sensitivity to a pre-addiction state and eliminating the neurological basis of physical craving.

Texas $50M Clinical Trials

UTHealth Houston and UTMB Health are conducting the largest government-funded ibogaine research program in US history, focused on opioid use disorder. Results are expected to be transformative.

Long-Term Abstinence Rates

Studies show 50–80% of ibogaine-treated opioid patients report abstinence at 3 months, with many maintaining sobriety at 12+ months — far exceeding rates for conventional treatment.

The Opioid Crisis and Ibogaine's Promise

The United States opioid crisis claims over 80,000 lives annually. Existing treatments — methadone, buprenorphine (Suboxone), and naltrexone — are maintenance medications that manage dependence rather than resolving it. Patients often remain on these medications for years or decades, and relapse rates remain high. Ibogaine offers something fundamentally different: a single-session intervention that can interrupt the neurological basis of opioid dependence and create a genuine window for lasting recovery.

The clinical evidence is compelling. A 2014 study published in the Journal of Psychoactive Drugs found that 50% of opioid-dependent patients treated with ibogaine reported no opioid use at 12-month follow-up. A 2017 study in the American Journal of Drug and Alcohol Abuse found significant reductions in withdrawal severity scores within 24 hours of ibogaine administration. Multiple observational studies from ibogaine clinics in Mexico and Costa Rica report similar results.

Why Integration Support Is Critical

Ibogaine creates a neurological and psychological window — typically 2–4 weeks following treatment — during which the brain is unusually plastic and receptive to new patterns. Patients who receive structured integration support during this window have dramatically better long-term outcomes than those who do not. This is why the role of the ibogaine integration coach is as important as the clinical facilitator — and why demand for certified integration coaches is growing alongside demand for clinical staff.

Does ibogaine cure opioid addiction?

Ibogaine is not a cure, but it is a powerful intervention. It interrupts physical withdrawal and dramatically reduces cravings, creating a window for behavioral change. Long-term outcomes depend heavily on post-treatment integration support, lifestyle changes, and addressing underlying trauma.

Can ibogaine be used for fentanyl addiction?

Yes, but fentanyl cases require additional care due to fentanyl's potency and long half-life. Some clinics require a transition from fentanyl to a shorter-acting opioid before ibogaine treatment. Clinical facilitators trained in ibogaine protocols are equipped to manage these cases.

How does ibogaine compare to methadone or Suboxone?

Methadone and buprenorphine are maintenance medications — they manage dependence without resolving it. Ibogaine aims to interrupt dependence entirely in a single session. The approaches are not mutually exclusive; some patients use maintenance medication to stabilize before ibogaine treatment.

Where can opioid patients get ibogaine treatment?

Currently, ibogaine treatment for opioid use disorder is available at licensed clinics in Mexico, Costa Rica, Portugal, and other countries where ibogaine is legal. Texas's clinical trials may eventually make treatment available in the US.